CURRENT FINANCIAL DATA

Disclosure concerning Optimo Holdings, Inc.

In November 2019 Optimo entered into an agreement with Kraig Biocraft Laboratories to provide consulting services including; investor relations,  media purchasing and news coverage and website traffic to our investor portal. Optimo will receive twenty five thousand dollars a month for costs associated with the internet media purchases. Optimo has been compensated previously and currently does not own any shares of Kraig Biocraft Laboratories.

Disclosure concerning Hansel Capital, LLC

Kraig Biocraft Laboratories has contracted with Hansel Capital, LLC to provide ongoing investor and media relations services.